tbuckley/cabot-search huggingface dataset:
PS2-4 Phase 1/2 study of HER3-DXd in HER3-expressing metastatic breast cancer: Subgroup analysis by HER2 expression
Authors: Hiroji Iwata, Ian E. Krop, Norikazu Masuda, Toru Mukohara, Shunji Takahashi, Takahiro Nakayama, Kenichi Inoue, Tatsuya Toyama, Yutaka Yamamoto, Ricardo H. Alvarez, Masato Takahashi, Akihiko Osaki, Shoichi Ohwada, Joseph Mostillo, Yoshimi Tanaka, David Sternberg, Dalila Sellami
Journal: Annals of Oncology (2023)
Mechanics in the nervous system: From development to disease
Authors: Eva K. Pillai, Kristian Franze
Journal: Neuron (2023)

Physical forces are ubiquitous in biological processes across scales and diverse contexts. This review highlights the significance of mechanical forces in nervous system development, homeostasis, and disease. We provide an overview of mechanical signals present in the nervous system and delve into mechanotransduction mechanisms translating these mechanical cues into biochemical signals. During development, mechanical cues regulate a plethora of processes, including cell proliferation, differentiation, migration, network formation, and cortex folding. Forces then continue exerting their influence on physiological processes, such as neuronal activity, glial cell function, and the interplay between these different cell types. Notably, changes in tissue mechanics manifest in neurodegenerative diseases and brain tumors, potentially offering new diagnostic and therapeutic target opportunities. Understanding the role of cellular forces and tissue mechanics in nervous system physiology and pathology adds a new facet to neurobiology, shedding new light on many processes that remain incompletely understood.
SY17-1 Evidence and clinical practice of peptide receptor radionuclide therapy for unresectable neuroendocrine tumors
Authors: Noritoshi Kobayashi, Tumugi Jono, Motokazu Sato, Yuma Takeda, Naoki Okubo, Risa Fukui, Akihiro Suzuki, Motohiko Tokuhisa, Yasushi Ichikawa
Journal: Annals of Oncology (2023)
MO18-6 Predictive value of CDC37 gene expression for regorafenib in metastatic colorectal cancer (mCRC)
Authors: Hiroyuki Arai, Tadamichi Denda, Yohei Kubota, Hiroyuki Takeda, Ayako Doi, Yoshiki Horie, Kumiko Umemoto, Naoki Izawa, Yu Sunakawa
Journal: Annals of Oncology (2023)
PS4-3 Survival analysis of m-FOLFOXIRI plus cetuximab vs. bevacizumab in RAS wild-type mCRC: The DEEPER trial (JACCRO CC-13)
Authors: Akihito Tsuji, Izuru Endo, Kenji Kobayashi, Yuji Miyamoto, Tetsuya Kusumoto, Yasuhiro Yuasa, Keisuke Miwa, Mitsugu Kochi, Tamotsu Sagawa, Masahito Kotaka, Yutaro Kubota, Yu Sunakawa, Takashi Sekikawa, Masato Nakamura, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii
Journal: Annals of Oncology (2023)
MO19-1 Definitive chemoradiation therapy with docetaxel, nedaplatin, and 5-fluorouracil (DNF-R) for locally advanced esophageal cancer – long-term follow-up
Authors: Hiroyuki Ohnuma, Kota Hamaguchi, Naotaka Hayasaka, Masanori Sato, Kazuyuki Murase, Kohichi Takada, Yuki Fukushima, Takaaki Tuchiya, Tomokazu Hasegawa, Masanori Someya, Koh-Ichi Sakata, Junji Kato
Journal: Annals of Oncology (2023)
MO16-3 Clinical relevance of comprehensive genome profiling using real-world data in colorectal cancer
Authors: Yoshinaga Okugawa, Takahito Kitajima, Takumi Fujiwara, Emi Teramoto, Maki Nakamura, Makoto Ikejiri, Ryotaro Hashizume, Hiroshi Imai, Yasutaka Tono, Kanako Saito, Ikuyo Mochiki, Satoshi Tamaru, Toshiro Mizuno, Yuji Toiyama
Journal: Annals of Oncology (2023)
MO3-3 Phase II study of S-1+CDDP with concurrent TRT followed by durvalumab for unresectable LA-NSCLC in Japan (SAMURAI)
Authors: Shigeru Tanzawa, Hisashi Tanaka, Megumi Inaba, Junya Nakamura, Kazuhiko Shibata, Takayuki Kishikawa, Masanao Nakashima, Keiichi Fujiwara, Tadashi Kohyama, Hiroo Ishida, Toshihiro Misumi, Kenshiro Shiraishi, Noriyuki Matsutani, Nobuhiko Seki, SAMURAI Study Group
Journal: Annals of Oncology (2023)
MO3-4 Radiotherapy technique recommendation based on radiomics for non-small cell lung cancer (NSCLC) patients
Authors: Eva Y.W. Cheung, Virginia Hy Kwong, Kenneth Hk Kwan, Matthias Ky Lui, Vincent Tw Li, Ryan St Lee, William Kp Ham, Ellie Sm Chu, Ricky Wk Wu
Journal: Annals of Oncology (2023)
Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidase
Authors: Ruipeng Lei, Wooseob Kim, Huibin Lv, Zongjun Mou, Michael J. Scherm, Aaron J. Schmitz, Jackson S. Turner, Timothy J.C. Tan, Yiquan Wang, Wenhao O. Ouyang, Weiwen Liang, Joel Rivera-Cardona, Chuyun Teo, Claire S. Graham, Christopher B. Brooke, Rachel M. Presti, Chris K.P. Mok, Florian Krammer, Xinghong Dai, Ali H. Ellebedy, Nicholas C. Wu
Journal: Immunity (2023)
Reprogramming tumor-associated macrophages to outcompete endovascular endothelial progenitor cells and suppress tumor neoangiogenesis
Authors: Mytrang H. Do, Wei Shi, Liangliang Ji, Erik Ladewig, Xian Zhang, Raghvendra M. Srivastava, Kristelle J. Capistrano, Chaucie Edwards, Isha Malik, Briana G. Nixon, Efstathios G. Stamatiades, Ming Liu, Shun Li, Peng Li, Chun Chou, Ke Xu, Ting-Wei Hsu, Xinxin Wang, Timothy A. Chan, Christina S. Leslie, Ming O. Li
Journal: Immunity (2023)
MO18-4 RAS status in ctDNA and efficacy of FOLFIRI plus ramucirumab in 2nd-line therapy for RAS wild-type mCRC: JACCRO CC-16AR
Authors: Yu Sunakawa, Hisateru Yasui, Masato Matsuura, Takashi Mine, Yasuhiro Yuasa, Takanori Watanabe, Tatsuya Kinjo, Yoshihiro Okita, Hiroyuki Okuyama, Satoshi Yuki, Koki Miyakawa, Ayana Kobara, Wataru Ichikawa, Masashi Fujii, Akihito Tsuji
Journal: Annals of Oncology (2023)
JS04-1 Clinical practice guidelines in cardio-oncology and the definition of cancer therapy-related cardiovascular toxicity
Authors: Kazuhiro Sase
Journal: Annals of Oncology (2023)

The European Society of Cardiology (ESC) recently published much-anticipated cardio-oncology clinical practice guidelines (CPGs). The new definition of cancer treatment-related cardiovascular toxicity (CTR-CVT) and the personalized care algorithms before, during, and after cancer treatment illustrate the scope and logic of the ESC-CPGs. The scope was cancer treatment-related cardiac dysfunction (CTRCD) when the experts discussed the need for clinical guidance on cardiotoxicity in 2013. Since then, developments of consensus recommendations and guidelines have facilitated the standardization, including the revised terminology for heart failure in the Common Terminology Criteria for Adverse Events (CTCAE) version 5.
MO1-4 Efficacy of immune checkpoint inhibitors plus chemotherapy for TTF-1-negative non-squamous non-small cell lung cancer
Authors: Hirokazu Iso, Kakeru Hisakane, Erika Mikami, Satoru Matsuki, Kenichiro Atsumi, Kohji Nagata, Masahiro Seike, Takashi Hirose
Journal: Annals of Oncology (2023)
MO17-2 Multicenter retrospective study of vulnerable patients with metastatic colorectal cancer: Results of second-line therapy
Authors: Kentaro Kawakami, Yosuke Kito, Seiichiro Mitani, Kaori Hino, Naoki Izawa, Fumiyasu Hanamura, Yoshiyuki Yamamoto, Hirokazu Shoji, Azusa Komori, Shogen Boku, Kenji Tsuchihashi, Eishi Baba, Kyoko Kato, Yoshikane Nonagase, Toshihiko Matsumoto, Mitsuhiro Furuta, Hisato Kawakami
Journal: Annals of Oncology (2023)
MO7-4 Impact of biliary drainage for pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil and folinic acid
Authors: Kazuo Nishikawa, Yoshihito Kubotsu, Mototsugu Shimokawa, Taiga Otsuka, Taro Shibuki, Junichi Nakazawa, Shiho Arima, Keisuke Miwa, Futa Koga, Yujiro Ueda, Hozumi Shimokawa, Shigeyuki Takeshita, Ayumu Hosokawa, Tatsunori Sakai, Hisanobu Oda, Shuji Arita, Machiko Kawahira, Tsuyoshi Shiraawa, Toshihiko Mizuta, Kenji Mitsugi
Journal: Annals of Oncology (2023)
PS4-1 Atezolizumab following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
Authors: Akira Ooki, Keisho Chin, Hideaki Bando, Shogo Kumagai, Daisuke Kotani, Saori Mishima, Takumi Habu, Takahiro Tsushima, Hiroki Hara, Shigenori Kadowaki, Ken Kato, Yamaguchi Kensei, Shun-Ichiro Kageyama, Hidehiro Hojo, Masaki Nakamura, Hidenobu Tachibana, Masashi Wakabayashi, Makoto Fukui, Nozomu Fuse, Hiroyoshi Nishikawa, Takashi Kojima
Journal: Annals of Oncology (2023)
MO7-6 Differences between tissue and blood specimens in CGP of pancreatic cancer from a real-world data of C-CAT
Authors: Toshifumi Doi, Takeshi Ishikawa, Tomoki Sakakida, Ryuichi Morita, Seita Kataoka, Hayato Miyake, Masahiro Iwasaku, Naohisa Yoshida, Michihisa Moriguchi, Yoshio Sogame, Hiroaki Yasuda, Hideyuki Konishi, Koichi Takayama, Yoshito Itoh
Journal: Annals of Oncology (2023)
MO6-6 Treatment effect of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma aiming at curative conversion therapy
Authors: Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Tatsuya Taniguchi, Yutaka Kawano, Tsutomu Masaki, Tetsuji Takayama
Journal: Annals of Oncology (2023)
Single-cell analysis of memory B cells from top neutralizers reveals multiple sites of vulnerability within HCMV Trimer and Pentamer
Authors: Matthias Zehner, Mira Alt, Artem Ashurov, Jory A. Goldsmith, Rebecca Spies, Nina Weiler, Justin Lerma, Lutz Gieselmann, Dagmar Stöhr, Henning Gruell, Eric P. Schultz, Christoph Kreer, Linda Schlachter, Hanna Janicki, Kerstin Laib Sampaio, Cora Stegmann, Michelle D. Nemetchek, Sabrina Dähling, Leon Ullrich, Ulf Dittmer, Oliver Witzke, Manuel Koch, Brent J. Ryckman, Ramin Lotfi, Jason S. McLellan, Adalbert Krawczyk, Christian Sinzger, Florian Klein
Journal: Immunity (2023)
MO6-2 Regorafenib plus tislelizumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma (HCC)
Authors: Chienhuai Chuang, Tsung-Hao Liu, Meng-Chi Hsu, Mo-Jung Chang, Ann-Lii Cheng, Chiun Hsu
Journal: Annals of Oncology (2023)
P29-10 Actionable genomic alterations in Filipino cancer patients using next-generation sequencing (NGS) liquid biopsy test
Authors: Mel Valerie Cruz Ordinario, Cyrielle Marie N Atutubo, Joanmarie C. Balolong-Garcia, Mary Anne B Cruz-Ignacio, Michelle Joane E Alcantara-Uy, Cristina G. Domingo, Yancel Donna L Mascardo-Mercado, Dean Marvin P Pizarro, Kristle May R Cortez, Angelica C. Gallespen, Dawn Lynn P Guardiario, Raiza S. Marave, Jessa Gilda P Pandy, Ana Eloise Bianca A Peralta, Carlos Dy, Marcelo Severino B Imasa, Rubi K. Li, Marie Belle Dc Francia
Journal: Annals of Oncology (2023)
MO40-4 DCF regimen might be useful as neo-adjuvant chemotherapy for esophageal cancer from our institutional experience
Authors: Kazuma Kobayashi, Kunihito Matsuguma, Shinichiro Kobayashi, Yasuhiro Maruya, Ryo Matsumoto, Hiromitsu Shinagawa, Koki Kurotaki, Taiichiro Kosaka, Yusuke Inoue, Satomi Okada, Toshiyuki Adachi, Sayaka Kuba, Michi Morita, Hajime Matsushima, Akihiko Soyama, Tomohiko Adachi, Shinichiro Ito, Masaaki Hidaka, Kengo Kanetaka, Susumu Eguchi
Journal: Annals of Oncology (2023)
MO19-3 Subgroup analyses of phase II study of weekly paclitaxel in advanced esophageal cancer that had previously received docetaxel-containing chemotherapy
Authors: Koji Nakashima, Takayuki Ando, Hiroki Yoshida, Miho Sakumura, Motoo Nomura, Manabu Muto, Hirofumi Fujii, Yoshiki Horie, Hiroyuki Takeda, Takako Yoshii, Yoshihiro Tahara, Chikatoshi Katada, Kenichi Yoshimura, Ishikawa Hideki, Ayumu Hosokawa
Journal: Annals of Oncology (2023)
MO56-1 Randomized phase II study of zoledronate dosing every 4 versus 8 weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312)
Authors: Motohiro Tamiya, Akito Hata, Takashi Nishimura, Yu Hidaka, Masahide Mori, Tomonori Hirashima, Naoto Takase, Toshihiko Kaneda, Hisashi Onishi, Kazumi Nihsimo, Satoshi Morita, Nobuyuki Katakami
Journal: Annals of Oncology (2023)
MO31-3 Association between tumor mutation burden and oncogenic mutation affecting the immune system of patients with non-small cell lung cancer
Authors: Takayuki Kobayashi, Makiko Yomota, Masachika Ikegami, Yuji Uehara, Taiki Hakozaki, Kana Hashimoto, Shoko Kawai, Kosuke Narita, Kageaki Watanabe, Yukio Hosomi
Journal: Annals of Oncology (2023)
MO5-4 Off-label or unapproved drug use and physicians' expectations of life insurance companies
Authors: Yukiko Higuchi, Hiroshi Koseki, Naoki Watanabe, Megumi Nonoda, Kazunari Hirate, Takuya Iwata, Tomomi Funao, Shinsuke Nakahara, Tsunehiro Sato, Daisaku Kato, Yukio Honjo, Noriyuki Katumata
Journal: Annals of Oncology (2023)
MO33-2 Retrospective analysis of urothelial carcinoma treated with enfortumab vedotin at our institution
Authors: Toru Imai, Shosuke Kita, Tatsunori Shimoi, Shu Yazaki, Momoko Tokura, Asuka Kawachi, Hitomi S. Okuma, Eijiro Nakamura, Motoko Arakaki, Ayumi Saito, Kasumi Yamamoto, Aiko Maejima, Yuki Kojima, Tadaaki Nishikawa, Kazuki Sudo, Emi Noguchi, Yoshiyuki Matsui, Yasuhiro Fujiwara, Kan Yonemori
Journal: Annals of Oncology (2023)
MO3-6 The elderly subgroup analysis in real world survey (CRIMSON) of concurrent chemoradiotherapy in locally advanced NSCLC
Authors: Akihiro Tamiya, Yuko Oya, Hayato Kawachi, Hirotaka Matsumoto, Yuki Sato, Taiichiro Otsuki, Go Saito, Hidekazu Suzuki, Yasushi Fukuda, Satoshi Tanaka, Yoko Tsukita, Masaki Kanazu, Yoshihiko Sakata, Yuki Nakatani, Shunsuke Teraoka, Ichiro Nakachi, Asuka Okada, Satoshi Hara
Journal: Annals of Oncology (2023)
MO41-2 Circulating tumor DNA (ctDNA) predicts prognosis in triple-negative breast cancer patients: A systematic review
Authors: Edellin F. Lokanata, Beatrix L. Frandi, Jeremiah H. Wijaya, Alexander E. Purnomo, Gabriella H. Tumiwa, Michael G. Lokanata, Rivaldo S. Heriyanto, Andree Kurniawan
Journal: Annals of Oncology (2023)
PS2-2 T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04
Authors: Junji Tsurutani, Shanu Modi, Joo Hyuk Sohn, Eriko Tokunaga, Naoki Niikura, Yeon Hee Park, Keun Seok Lee, Yee Soo Chae, Xiaojia Wang, Wei Li, Seock-Ah Im, Binghe Xu, Yen-Shen Lu, Dhiraj Gambhire, Soichiro Nishijima, Yuji Nishiyama, Masahiro Sugihara
Journal: Annals of Oncology (2023)
P21-7 A case of male breast cancer with long-term disease control with fulvestrant + abemaciclib
Authors: Miyuki Takahashi, Syu Inagaki, Yuki Takane, Keisuke Taguchi, Sayano Nagasawa, Yuki Suematsu, Masahiro Yan, Mariko Masubuchi, Nobuhisa Teranishi, Kazuhiko Wakabayashi, Hiroyuki Uetake, Yutaka Itoh
Journal: Annals of Oncology (2023)
MO60-4 Tryptophan is the prognostic factor in patients with unresectable pancreatic cancer
Authors: Kei Saito, Suguru Mizuno, Yousuke Nakai, Tatsunori Suzuki, Kazunaga Ishigaki, Ryunosuke Hakuta, Naminatsu Takahara, Tomotaka Saito, Tsuyoshi Hamada, Hiroyuki Isayama, Mitsuhiro Fujishiro
Journal: Annals of Oncology (2023)
MO57-4 Association of Glasgow prognostic score with efficacy and safety of first-line osimertinib in EGFR mutated NSCLC (OSI-FACT exploratory analysis)
Authors: Yuko Oya, Yoshihiko Sakata, Shinya Sakata, Motohiro Tamiya, Hidekazu Suzuki, Ryota Shibaki, Asuka Okada, Hiroshi Kobe, Hirotaka Matsumoto, Taiichiro Otsuki, Yuki Sato, Masaki Kanazu, Go Saito, Yoko Tsukita, Megumi Inaba, Hideki Ikeda, Daisuke Arai, Hirotaka Maruyama, Satoshi Hara, Takuro Sakagami
Journal: Annals of Oncology (2023)
MO38-1 Phase 1 study of ABBV-155 ± paclitaxel in relapsed/refractory solid tumors: Results in Japanese patients
Authors: Toshio Shimizu, Kan Yonemori, Yasutoshi Kuboki, Anthony Tolcher, Misaki Kurokawa, Wijith Munasinghe, Andrew Phillips, Andrew Souers, Eric Johnson, Lei He, Aaron Weitzman, John Powderly, Patricia Lorusso, Yoichi Naito
Journal: Annals of Oncology (2023)
MO35-6 Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study)
Authors: Kei Morikawa, Saori Takata, Hisashi Tanaka, Kazuya Horiuchi, Yusuke Okuma, Kenzo Soejima, Hideyuki Nakagawa, Yoshiro Nakahara, Yoshitaka Seki, Akihiro Bessyo, Nobumasa Takahashi, Kentaro Hayashi, Takeo Endo, Ren Takeyama, Toshiya Maekura, Nagio Takigawa, Katsuhisa Horimoto, Noriyuki Matsutani, Nobuhiko Seki
Journal: Annals of Oncology (2023)
P63-3 A pivotal role of interdisciplinary team medicine in lenvatinib plus pembrolizumab therapy against advanced endometrial cancer
Authors: Kenzo Sonoda, Yukiko Sadamatsu, Yuka Ishibashi, Masao Okadome, Shinichiro Katsuma, Ai Nio, Takeshi Murakami, Shinichiro Yamaguchi, Rina Nagayama, Kazuya Ariyoshi, Toshiaki Saito
Journal: Annals of Oncology (2023)
MO3-2 Influence of durvalumab consolidation on pneumonitis after chemoradiotherapy for unresectable non-small cell lung cancer
Authors: Saori Murata, Hidehito Horinouchi, Momoko Morishita, Sawako Kaku, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Noboru Yamamoto, Kae Okuma, Masahiko Kusumoto, Yuichiro Ohe
Journal: Annals of Oncology (2023)
MO66-6 Multicenter prospective observational study on treatment and prognosis of patients with primary small bowel cancer
Authors: Haruhiro Yamashita, Masaru Inagaki, Hideki Kawamura, Masahiro Shimoyamada, Kazuhiko Hatate, Takuji Naka, Toru Yamasaki, Tetsuya Kusumoto, Kazuhiro Toyota, Noboru Yahara, Naoko Hayashi, Toshihisa Kimura, Tamotsu Sagawa, Takashi Yamaguchi, Hideki Aoki, Hirofumi Kawanaka, Fujio Makita, Takeshi Kajiwara, Masayuki Furukawa, Takeshi Katou
Journal: Annals of Oncology (2023)
P43-3 A case of complete response to entrectinib in NTRK fusion gene-positive parotid carcinoma
Authors: Etsuko Moriyama, Sachiko Nagasu, Toshimitsu Tanaka, Hirona Shigyo, Yasutaka Shimotsuura, Kurita Takashi, Takeharu Ono, Hirohito Umeno, Jun Akiba, Yoshiki Naito, Keisuke Miwa
Journal: Annals of Oncology (2023)
MO46-2 Efficacy and safety of palliative radiation therapy for tumor bleeding in patients with advanced pancreatic cancer
Authors: Taro Shibuki, Mitsuhito Sasaki, Shota Yamaguchi, Kanae Inoue, Tomonao Taira, Hiroki Eguchi, Kei Okumura, Tomoyuki Satake, Kazuo Watanabe, Hiroshi Imaoka, Shuichi Mitsunaga, Takeshi Fujisawa, Kento Tomizawa, Hidekazu Oyoshi, Masaki Nakamura, Hidehiro Hojo, Masafumi Ikeda
Journal: Annals of Oncology (2023)
MO57-5 Multicenter retrospective study to evaluate necitumumab plus CDDP/GEM after ICIs in advanced squamous-cell lung cancer in Japan (NINJA study)
Authors: Shigeru Tanzawa, Hiroshige Yoshioka, Eisaku Miyauchi, Kiichiro Ninomiya, Toshihiro Misumi, Nobuhiko Seki, Group Ninja Study
Journal: Annals of Oncology (2023)
MO58-2 Differences in treatment response to CDK4/6 inhibitors and endocrine therapy between HER2-negative and HER2-low expression groups
Authors: Reo Omori, Shinya Tokunaga, Yuichiro Nishibori, Yuki Nakatani, Yuko Akaishi, Ayako Tanaka, Kohei Akiyoshi, Haruko Daga
Journal: Annals of Oncology (2023)
MO35-5 Long-term efficacy and safety from the CROWN study in Japanese patients with ALK+ advanced non-small cell lung cancer
Authors: Shunsuke Teraoka, Hidetoshi Hayashi, Yasushi Goto, Makoto Nishio, Shunichi Sugawara, Takako Inoue, Satoshi Oizumi, Terufumi Kato, Shigeyuki Toyoizumi, Masakazu Matsumura, Rossella Messina
Journal: Annals of Oncology (2023)
P37-6 Potential radiosensitizers for betel nuts-related head and neck squamous cell carcinoma in Taiwan
Authors: Jo-Pai Chen, Jui-Ying Chang, Ruey-Long Hong
Journal: Annals of Oncology (2023)

Betel nut chewing might contribute to strong invasion & treatment refractoriness in HNSCC from Taiwan. Betel-nuts exposed HNSCC cell line, TW2.6, had high PDL1, defective p53 mutation, p16 loss, & BCL2 overexpression. In our studies, PI3K/AKT/mTOR inhibitors, anti-angiogenesis therapies, CDK4/6 inhibitors, DDR interventions, epigenetic modifications, and immunotherapy-containing regimens will be future combination options. The genomic signature of TW2.6 has been also figured out in our study (AACR2020) and molecularly-guided novel interventions will be designed.
MO29-3 Transition of childhood cancer survivors to adult care – what we have learned from the experience of Cancer Survivorship Clinic over the past 3 years
Authors: Tomoko Taniyama, Chikako Shimizu, Midori Kadowaki, Yoko Takada, Hiroyuki Shichino, Hideko Uryu, Takeshi Inagaki, Hajime Oishi, Akiyo Tanabe, Makiko Hashimoto, Syuji Kubota, Chikako Kiyotani, Kimikazu Matsumoto
Journal: Annals of Oncology (2023)
MO2-7 A multicenter prospective observational study of pre-existing autoantibodies in patients with small-cell lung cancer treated with ICI
Authors: Akito Hata, Yuki Sato, Satoru Fujiwara, Yoko Kida, Takahiro Masuda, Hisanori Amimoto, Hirotaka Matsumoto, Kotoko Miyoshi, Kojiro Otsuka, Keisuke Tomii
Journal: Annals of Oncology (2023)
P57-1 Real-world treatment outcomes of metastatic biliary tract cancer in Japan: Tokushukai REAl-world Data project; TREAD 04
Authors: Rai Shimoyama, Yoshinori Imamura, Kiyoaki Uryu, Takahiro Mase, Masataka Taguri, Yoshiaki Fujimura, Maki Hayashi, Keiji Sawamukai, Nobuaki Shinozaki, Hironobu Minami
Journal: Annals of Oncology (2023)
P47-7 Oral 5-FU+/-bevacizumab should be basically used for first-line chemotherapy for elderly colorectal cancerous patients
Authors: Kazuma Kobayashi, Kunihito Matsuguma, Yusuke Inoue, Satomi Okada, Toshiyuki Adachi, Shun Nakamura, Shinichiro Kobayashi, Yasuhiro Maruya, Ryo Matsumoto, Taiichiro Kosaka, Sayaka Kuba, Michi Morita, Takanobu Hara, Hajime Imamura, Akihiko Soyama, Tomohiko Adachi, Shinichiro Ito, Masaaki Hidaka, Kengo Kanetaka, Susumu Eguchi
Journal: Annals of Oncology (2023)
MO34-4 Advanced hepatocellular carcinoma viral status and immunotherapy efficacy: A propensity-score matched analysis
Authors: Qin Jian Low, Joseph J. Zhao, Rachel Su Jen Wong, Carol Lf Ho, Zhaoting Lin, Hon Lyn Tan, Joan Re Choo, Gloria Chan, Jingshan Ho, Yugarajah Asokumaran, Raghav Sundar, Cheng Ean Chee, Wei Peng Yong
Journal: Annals of Oncology (2023)
P30-1 Comparison of efficacy of atezolizumab and bevacizumab treatment for hepatocellular carcinoma between tyrosine kinase inhibitor-naive and -experienced patients
Authors: Norihiro Nishijima, Genki Takahashi, Tetsuya Shinji, Takayuki Kitano, Noriko Kitano, Toshinari Shiba, Meidai Kasai, Yoshiki Nando, Takayoshi Nakajima, Yoshiyuki Sakai, Tomotaro Kawazoe, Shinichi Ikuta, Tsukasa Aihara, Kazutaka Kurokochi, Kiyohiko Kishi, Yukio Osaki, Naoki Yamanaka
Journal: Annals of Oncology (2023)
MO2-4 Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in older adults aged over 75 years
Authors: Sho Saeki, Yuta Yamanaka, Takayasu Kurata, Kageaki Watanabe, Yukio Hosomi, Hidehito Horinouchi, Yuichiro Ohe, Yoshiro Nakahara, Tetsuhiko Asao, Yukari Tsubata, Yu Fujita, Jun Sakakibara Konishi, Hidenori Mizugaki, Mayu Ohuchi, Shigehiro Yagishita, Akinobu Hamada
Journal: Annals of Oncology (2023)
MO52-4 Examination of patient characteristics in breast cancer patients who underwent BRCA genetic testing, according to reason for taking the test
Authors: Ayaka Sakakibara, Hiroshi Ishiguro, Midori Oakabe, Kiyoko Hata, Manami Kojima, Ayako Nakame, Akihiro Fujimoto, Yuki Ichinose, Asami Nukui, Aya Asano, Hiroko Shimada, Kazuo Matsuura, Akihiko Osaki, Toshiaki Saeki
Journal: Annals of Oncology (2023)
MO18-2 Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study
Authors: Naohisa Yoshida, Yoshiaki Kuriu, Jyun Ikeda, Michihiro Kudo, Toshihiko Kirishima, Tetsuya Okayama, Kimiharu Miyagawa, Takeshi Takagi, Masayoshi Nakanishi, Yoshito Itoh, Eigo Otsuji
Journal: Annals of Oncology (2023)
MO1-1 LIGHT-NING 2nd interim analysis: Early safety of 1L nivolumab + ipilimumab +/- chemotherapy for NSCLC in Japan
Authors: Koichi Azuma, Hisao Imai, Takashi Kijima, Kazuma Kishi, Haruhiro Saito, Teppei Yamaguchi, Hidetoshi Hayashi, Yoshimasa Shiraishi, Kohei Fujita, Satoshi Watanabe, Satoru Kitazono, Tatsuro Fukuhara, Osamu Hataji, Yukihiro Toi, Hideaki Mizutani, Yusuke Hamakawa, Makoto Maemondo, Tomoyuki Ohsugi, Keisuke Suzuki, Hidehito Horinouchi, Yuichiro Ohe
Journal: Annals of Oncology (2023)
MO4-2 Phase 1 study of ABBV-400, a novel anti-Met antibody drug conjugate, in advanced solid tumors
Authors: Toshio Shimizu, John Powderly, Manish R. Sharma, Xiaowen Guan, Athanasios Vasilopoulos, Martha Li, Rui Li, Alexis Cunningham, Regina Reilly, Gladys Morrison-Thiele, Kevin Freise, Martha Neagu Aristide, D. Ross Camidge
Journal: Annals of Oncology (2023)